[WIRB - IAA] A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator

Julie Graff

Study Purpose

The purpose of this study is to determine the safety and side effects, good and/or bad, of each combination of study drugs.

Another purpose of the study is to measure the effects of the study drug, its mechanism of action on tumor cells and determine how the body processes and gets rid of the study drug.

Medical Condition(s)

Metastatic castration resistant prostate cancer (mCRPC)

Eligibility Criteria

-Subjects should have metastatic castration resistant prostate cancer
-Subjects should have at least one prior treatment with an FDA approved androgen-signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide) in the castration-resistant setting
-Subjects should be willing to have a research tumor biopsy (if medically feasible)

Age Range

18 - NA

Healthy Volunteers Needed


Duration of Participation

Participants will receive the investigational drugs for up to 2 years. There will be one follow up visit 30 days after the last dose of the study drugs. After discontinuation of the study drugs, participants will be contacted by phone every 3 months. Participants will be followed for up to 2.5 years from the beginning of study participation.

Minors Included



Clinical Trials Information Line: Phone 503-494-1080 or


Parker Institute for Cancer Immunotherapy

Recruitment End


Compensation Provided


Go Back